Netupitant/palonosetron - Helsinn

Drug Profile

Netupitant/palonosetron - Helsinn

Alternative Names: Akynzeo; Fosnetupitant/palonosetron; NEPA; NEPA - Helsinn; Palonosetron/netupitant

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Helsinn
  • Developer CJ HealthCare; Glenmark Pharmaceuticals Ltd; Helsinn; Purdue Pharma; Taiho Pharmaceutical; Vifor Pharma
  • Class Antiemetics; Isoquinolines; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Neurokinin 1 antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 31 Jul 2018 CJ Healthcare expects to launch netupitant/palonosetron for Chemotherapy-induced nausea and vomiting (Prevention) in South Korea by end of 2018
  • 09 Jul 2018 Launched for Chemotherapy induced nausea and vomiting (Prevention) in Nepal (PO)
  • 09 Jul 2018 Launched for Chemotherapy induced nausea and vomiting (Prevention) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top